Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2018 John Wiley & Sons, Inc. All rights reserved. Toxgnostics is an emerging term within the field of oncology. Currently, the systemic treatment of solid tumors often produces only a modest increase in survival rates, while concomitantly exposing the patient to a very real prospect of significant and potentially life-threatening toxicity. One example can be found in the management of stage 2 colorectal cancer. Toxgnostics is a more agnostic approach to identify germ line variants that influence toxicity. In the field of oncology, as with other specialties, there exists an abundance of practical guidance as to how best the clinician can deliver patient care. Chemotherapy prescription, due to its nature of prescribing highly toxic chemicals, has perhaps more guidance than most inhospital treatments. The aim of toxgnostics is to be able to apply any necessary modifications to a personalized prescription in a prospective manner, therefore mitigating any risks before the patient is exposed.

Original publication





Book title

Translational Toxicology and Therapeutics: Windows of Developmental Susceptibility in Reproduction and Cancer

Publication Date



691 - 710